DrNose offers a portable, IoT‑powered breath analysis device that detects disease markers in real time without invasive procedures. The handheld “electric nose” integrates up to eight specialized sensors and an “Intuitive AI” engine that interprets electronic patterns, enabling rapid screening at a cost‑effective price. By converting breath chemistry into diagnostic insights, DrNose provides early disease detection for clinicians and users in a non‑intrusive, affordable format.
Funding
Funding not disclosed
Founders
Product
Problem
Early disease detection often relies on invasive tests or expensive laboratory equipment, limiting accessibility and delaying diagnosis for many patients.
Solution
DrNose provides a portable, IoT‑enabled breath analysis device that captures exhaled volatile compounds and translates the electronic signatures from up to eight specialized sensors into diagnostic insights. Its proprietary “Intuitive AI” engine processes sensor data in real time without requiring deep‑learning models or GPU hardware, delivering rapid, on‑device results. Clinical trials have shown over 90% accuracy for lung and breast cancer detection, with additional studies underway for diabetes, asthma, and other conditions. By offering a non‑intrusive, cost‑effective screening tool, DrNose enables earlier intervention and expands diagnostic access beyond traditional clinical settings.
Target Audience
Primary users include primary care physicians, pulmonologists, oncologists, and other healthcare providers seeking rapid, non‑invasive screening tools, as well as health‑conscious individuals interested in early disease detection.
Features
- Up to eight dedicated chemical sensors to capture a broad spectrum of breath biomarkers
- “Intuitive AI” analytics that train quickly on sensor patterns without heavy computational resources
- Real‑time, on‑device result generation with cloud connectivity for data storage and remote review
- IoT architecture for secure firmware updates, device management, and integration with health IT systems
- Clinically validated accuracy exceeding 90% for lung and breast cancer screening
- Compact, battery‑operated form factor designed for point‑of‑care, home, or mobile use
- Affordable pricing model aimed at broad user adoption across diverse healthcare environments